Novartis Cuts 2,500 More Jobs In Drive To Save $1.6 Billion By 2010
Executive Summary
Novartis will cut another 2,500 full-time positions by the end of 2008, 1,700 of them from its pharmaceuticals business, as part of a plan to put the division back on its feet after a rocky 2007, CEO Daniel Vasella announced Dec. 13
You may also be interested in...
No Sales Model Left Behind: Novartis Joins Firms In Changing Market Focus
Novartis is joining the horde of pharmaceutical companies that are revamping their sales and marketing organizations in response to a U.S. market that is rapidly changing, at varying paces in different regions
No Sales Model Left Behind: Novartis Joins Firms In Changing Market Focus
Novartis is joining the horde of pharmaceutical companies that are revamping their sales and marketing organizations in response to a U.S. market that is rapidly changing, at varying paces in different regions
Galvus Safety Trial Reconsidered In Light Of Novartis Cost Concerns
Novartis' NDA for its oral type 2 diabetes drug Galvus (vildagliptin) will remain in a holding pattern in the U.S. until the firm has a clearer idea of whether it can gain FDA approval without excessive expenditures to gather additional safety data